DaVita (DVA) News Today

DaVita Inc. (NYSE:DVA) faces downward pressure on its shares today amid analyst downgrades, a fresh 52-week low and a significant data breach, despite management’s strong second-quarter performance.

• Positive Sentiment: DaVita highlighted its ability to navigate second-quarter headwinds with resilient financial results during its earnings call. DaVita Healthcare’s Resilient Earnings Call Amid Challenges
• Neutral Sentiment: TD Cowen maintains a “hold” rating on DVA, signaling a cautious view without changing its outlook. TD Cowen Remains a Hold on DaVita (DVA)
• Neutral Sentiment: Full transcript of DaVita’s Q2 2025 earnings call provides detailed management commentary on operations and outlook. DaVita Inc. (NYSE:DVA) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Summary of Q2 2025 earnings highlights management’s focus on cost controls and patient volume recovery. DaVita Inc (DVA) Q2 2025 Earnings Call Highlights
• Negative Sentiment: Analyst Barclays cut its price target to $160 from $169 and kept an “equal weight” rating, signaling lower upside expectations. Barclays Has Lowered Expectations for DaVita (NYSE:DVA) Stock Price
• Negative Sentiment: DaVita’s shares recently hit a new 52-week low, reflecting investor concerns over growth and industry pressures. DaVita (NYSE:DVA) Reaches New 52-Week Low
• Negative Sentiment: Over one million patients were impacted by a recent data breach, raising compliance and remediation cost concerns. Over 1 Million Impacted by DaVita Data Breach
• Negative Sentiment: Clinical patient data was stolen in a cyberattack on DaVita, potentially leading to regulatory scrutiny. Clinical Data Stolen in Cyber-Attack on Kidney Dialysis Provider DaVita